In the Shanghai cohort, 36 of 69 NSCLC tumors had EGFR mutation (52.17%), 49 of 103 CRC had KRAS mutation (47.57%), and 91 of 130 PTC had BRAF mutation (70%). This evidence concerns the gene EGFR and colorectal carcinoma.